Biotechnology Research · Brandenburg
KUPANDO is a pioneering biotech company developing disruptive therapies to address critical unmet medical needs with significant market potential in cancer and infectious diseases. Kupando’s disruptive approach harnesses the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists. Our lead candidate, KUP101, is a differentiated and competitive dual TLR agonist with a robust preclinical profile and a clear path to the clinic with a pipeline of multiple programs targeting oncology and infectious disease indications.